Vicore Pharma AB
Records under this name other than the patents Vicore Pharma AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
Showing 1 to 8 of 8 · Back to Vicore Pharma AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,835,471 | Use of angiotensin II agonists Lapsed on the fee record Ended Sep 16, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 16, 2022 | From the USPTO record |
| US 8,357,710 | Bicyclic angiotensin II agonists Lapsed on the fee record Ended Jan 22, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jan 22, 2021 | From the USPTO record |
| US 8,080,571 | Tricyclic angiotensin II agonists Lapsed on the fee record Ended Dec 20, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 20, 2019 | From the USPTO record |
| US 8,067,418 | Tricyclic angiotensin II agonists Lapsed on the fee record Ended Nov 29, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 29, 2019 | From the USPTO record |
| US 7,652,054 | Tricyclic Compounds Useful as Angiotensin II Agonists Term ended Term ended Apr 11, 2012 · High confidence | Term ended | Term ended Apr 11, 2012 | High confidence |
| US 8,124,638 | Tricyclic Compounds Useful as Angiotensin II Agonists Term ended Term ended Jan 4, 2010 · High confidence | Term ended | Term ended Jan 4, 2010 | High confidence |
| US 6,096,772 | Use of Angiotensin II type 1 receptor antagonists in the treatment of dyspeptic symptoms Lapsed on the fee record Ended Aug 1, 2004 · From the USPTO record | Lapsed on the fee record | Ended Aug 1, 2004 | From the USPTO record |
| US 5,977,159 | Medical use of an ace-inhibitor for treatment of dyspeptic symptoms Term ended Term ended no later than Nov 2, 2019 · Low confidence | Term ended | Term ended no later than Nov 2, 2019 | Low confidence |